ChemicalBook >> CAS DataBase List >>Selumetinib
Selumetinib
- CAS No.
- 606143-52-6
- Chemical Name:
- Selumetinib
- Synonyms
- 5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide;6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide;113183;CS-1912;AZD 6244;AZD-6224;umetinib;ARRY 142886;Selumetinib;Array142886
- CBNumber:
- CB81871940
- Molecular Formula:
- C17H15BrClFN4O3
- Molecular Weight:
- 457.68
- MDL Number:
- MFCD11977472
- MOL File:
- 606143-52-6.mol
Last updated:2024-06-30 15:45:59
Melting point | >219°C (dec.) |
---|---|
Density | 1.69 |
storage temp. | -20° |
solubility | Soluble in DMSO (up to 50 mg/ml) or in Ethanol (up to 2 mg/ml) |
form | Beige powder. |
pka | 14.20±0.10(Predicted) |
color | White |
Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 2 months. |
NCI Dictionary of Cancer Terms | |
FDA UNII | |
ATC code |
SAFETY
Risk and Safety Statements
Symbol(GHS) | GHS05,GHS07,GHS08 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
Signal word | Danger | |||||||||
Hazard statements | H317-H318-H361d-H373 | |||||||||
Precautionary statements | P262-P280-P312 | |||||||||
HS Code | 29349990 | |||||||||
NFPA 704 |
|
Selumetinib price More Price(41)
Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|---|
Cayman Chemical | 11599 | AZD 6244 ≥98% | 606143-52-6 | 10mg | $32 | 2025-03-01 | Buy |
Cayman Chemical | 11599 | AZD 6244 ≥98% | 606143-52-6 | 25mg | $55 | 2025-03-01 | Buy |
Cayman Chemical | 11599 | AZD 6244 ≥98% | 606143-52-6 | 50mg | $86 | 2025-03-01 | Buy |
Cayman Chemical | 11599 | AZD 6244 ≥98% | 606143-52-6 | 100mg | $109 | 2025-03-01 | Buy |
Tocris | 6815 | Selumetinib ≥98%(HPLC) | 606143-52-6 | 50 | $91 | 2022-12-16 | Buy |
Selumetinib Chemical Properties,Uses,Production
Indications and Usage
Selumetinib, 1 has a chemical name of 5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide. It was developed by British company AstraZeneca and is used to treat advanced non-small cell lung cancer (NSCLC). It is mainly used to treat bile duct cancer, colon cancer, NSCLC, etc. Currently, Selumetinib is in stage III clinical trials for treatment of NSCLC.Mechanisms of Action
Selumetinib is the first mitogenextracellular kinase (MEK1/2) inhibitor to be used in thyroid cancer clinical trials. It inhibits extracellular signal regulating kinase (ERK/2) and activates caspase to dramatically inhibit ERK1/2 phosphorylation.Clinical Research
In phase II clinical trials of radioiodine-refractory papillary thyroid carcinoma, 39 patients took daily oral doses of Selumetinib (100mg bid) for 28 days; results showed that 21 patients’ conditions stabilized (54%), 11 patients’ conditions worsened (28%), 49% patients’ conditions were stable for 16 weeks, 36% patients’ conditions were stable for 24 weeks, and survival terms did not progress to 32 weeks. Negative reactions mainly consisted of rashes (59%), diarrhea (44%), and weakness (41%). Some studies found that after treating 20 patients with thyroid cancer with Selumetinib (75mg bid) for 4 weeks, Selumetinib increased the iodine uptake and retention of patients with radioiodine-refractory papillary thyroid carcinoma. In a blind and random comparative study between a Selumetinib and Docetaxel (DOC) combination treatment group and DOC and placebo treatment group for 87 mutant NSCLSC patients, survival times were 9.4 months and 5.2 months, PFS were 5.3 months and 2.1 months, RR were 37% and 0%, thus showing dramatic differences. Selumetinib’s main negative reactions include neutrophil depletion, dermatitis, and respiratory failure.Description
Selumetinib (AZD6244; ARRY-142886) is an oral MEK inhibitor. In a randomized trial, NSCLC patients with wild-type KRAS were randomized to erlotinib alone or combination therapy with selumetinib, while mutant KRAS patients were randomized to selumetinib alone or combination therapy. The primary end points were PFS for the KRAS wild-type cohort and objective response rate (ORR) for the KRAS mutant cohort. Results were not impressive, with no PFS difference in the KRAS wild-type arm (2.4 vs. 2.1?months) and no ORR difference in the KRASmutated subgroup (0% vs. 10%). A planned trial of selumetinib in combination with the anti-PD-L1 antibody durvalumab has since been suspended (NCT03004105).Uses
It is a tight-binding, uncompetitive inhibitor of mitogen-activated protein kinase kinases (MEK) 1 and 2 currently in clinical development. It is useful as biomarker in human lung cancer cell. Potent MEK inhibitor.Definition
ChEBI: A member of the class of benzimidazoles that is 1-methyl-1H-benzimidazole which is substituted at positions 4, 5, and 6 by fluorine, (4-bromo-2-chlorophenyl)amino, and N-(2-hydroxyethoxy)aminocarbonyl groups, respectiv ly. It is a MEK1 and MEK2 inhibitor.target
MEK1storage
Store at -20°CReferences
1) Davies?et al. (2007),?AZD6244(ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamics relationship, and potential for combination in preclinical models; Mol. Cancer Ther.,?6?2209 2) Yeh?et al. (2007),?Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor; Clin. Cancer Res.,?13?1576 3) Catalanotti?et al. (2013),?Phase II trial of MEK inhibitor selumetinib(AZD6244) in patients with BRAFV600E/K-mutated melanoma; Clin. Cancer Res.,?19?2257 4) O’Neil?et al. (2011),?Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma; J. Clin. Oncol.,?29?2350 5) Khurum?et al. (2012),?A phase I dose escalation study of oral MK-2206 (allosteric Akt inhibitor) with oral selumetinib (AZD6244)(MEK 1/2 inhibitor) in patients with advanced or metastatic solid tumors; J. Clin. Oncol.,?30?e13599 6) Hainsworth?et al. (2010),?A phase II, open label, randomized study to assess the efficacy and safety of AZD6244 versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens; J. Thorac. Oncol.,?5?1630 7) Bodoky?et al. (2012),?A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy; Invest. New Drugs,?30?1216Selumetinib Preparation Products And Raw materials
Global( 313)Suppliers
Supplier | Tel | Country | ProdList | Advantage | |
---|---|---|---|---|---|
Hebei Mojin Biotechnology Co., Ltd | +8613288715578 | sales@hbmojin.com | China | 12470 | 58 |
Zhengzhou Anbu Chem Co.,Ltd | +86-0371-88006763; +8615988602810 | sales@anbuchem.com | China | 3000 | 58 |
Capot Chemical Co.,Ltd. | 571-85586718 +8613336195806 | sales@capotchem.com | China | 29797 | 60 |
Nanjing Finetech Chemical Co., Ltd. | 025-85710122 17714198479 | sales@fine-chemtech.com | CHINA | 885 | 55 |
ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 | ivan@atkchemical.com | China | 32686 | 60 |
career henan chemical co | +86-0371-86658258 | sales@coreychem.com | China | 29914 | 58 |
Hebei Guanlang Biotechnology Co., Ltd. | +86-19930503282 | alice@crovellbio.com | China | 8822 | 58 |
BOC Sciences | +1-631-485-4226 | inquiry@bocsci.com | United States | 19553 | 58 |
Beijing Yibai Biotechnology Co., Ltd | 0086-182-6772-3597 | sales04@yibaibiotech.com | CHINA | 419 | 58 |
Chongqing Chemdad Co., Ltd | +86-023-61398051 +8613650506873 | sales@chemdad.com | China | 39916 | 58 |
View Lastest Price from Selumetinib manufacturers
Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
---|---|---|---|---|---|---|---|---|
2024-06-22 | Selumetinib
606143-52-6
|
US $0.00 / KG | 1KG | 99% | 50000KG/month | Hebei Mojin Biotechnology Co., Ltd | ||
2024-06-19 | Selumetinib
606143-52-6
|
US $0.00 / KG | 1KG | 98% | 1000KGS | Zhengzhou Anbu Chem Co.,Ltd | ||
2023-02-18 | SeluMetinib
606143-52-6
|
US $0.00 / gram | 1gram | 99% | 10kg | Zhejiang J&C Biological Technology Co.,Limited |
- Selumetinib
606143-52-6
- US $0.00 / KG
- 99%
- Hebei Mojin Biotechnology Co., Ltd
- Selumetinib
606143-52-6
- US $0.00 / KG
- 98%
- Zhengzhou Anbu Chem Co.,Ltd
- SeluMetinib
606143-52-6
- US $0.00 / gram
- 99%
- Zhejiang J&C Biological Technology Co.,Limited
606143-52-6(Selumetinib)Related Search:
ARRY 142886
AZD 6244
Selumetinib
AZD624
5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-car
Selumetinib
5-(4-Bromo-2-chlorophenylamino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide
6-(4-Bromo-2-chlorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide
SeluMatinib(5-[(4-BroMo-2-chlorophenyl)aMino]-4-fluoro-N-(2-hydroxyethoxy)-1-Methyl-1H-benziMidazole-6-carboxaMide
AZD6244(SeluMetinib)
AZD6244; ARRY142886
SeluMetinib (AZD6244)
Array142886
AZD-6244(SeluMetinib)/AZD6244
5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carbox
AZD6244, ARRY-142886, ARRY-886
5-(4-BroMo-2-chlorophenylaMino)-4-fluoro-1-Methyl-1H-benziMidazole-6-carbohydroxaMic acid 2-hydroxyethyl ester
5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide Selumetinib (AZD6244)
AZD 6244
5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide
selumetinib (MEK inhibitor)
Selumetinib, >=98%
AZD-6224
Selumetinib, 99%, a highly selective MEK1 inhibitor
Selumetinib, Free BaseAZD6244ARRY-142886
Selumetinib (AZD6244) Selumetinib
ARRY-142886; SELUMETINIB;AZD-6244;ARRY142886
AZD6244 (ARRY142886, Selumetinib)
AZD6244 (Selumetinib,ARRY-142886)
113183
CS-1912
Selumetinib Base
umetinib
umetinib (AZD6244) SeL
1H-Benzimidazole-6-carboxamide, 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-
Selumetinib USP/EP/BP
Selumetinib D4
5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide
6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide
5-((4-Bromo-2-chlorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzodimidazol-6-carboxamide
Quinoxyfen Impurity 1
Selumetinib API
606143-52-6
60614-52-6
C17H15BrClFN4O3
MAPK
Inhibitors
Antineoplastic
apis
Aromatics
Heterocycles
Inhibitor
Intermediates & Fine Chemicals
Pharmaceuticals
API
Research